VCYT
VENTE TOTALE: 1 864 titres (~80 096,08 $ US)
- Insiders
- Bhanji Muna
- Total bought
- —
- Total sold
- $80,096
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-07
VCYT presents a compelling financial profile with exceptional liquidity (95) and strong fundamental momentum (85), reflecting a genuine turnaround into profitability with robust cash flow generation.
The first sentence of the analysis written for VCYT on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.6% | 66.9% | 68.7% | 65.7% | 66.1% | |
| Ebit Margin | 13.2% | 5.8% | -21.2% | -12.2% | -37.1% | |
| Ebitda Margin | 17.3% | 11.0% | -13.7% | -2.4% | -27.4% | |
| Operating Profit Margin | 14.3% | 3.6% | -23.8% | -13.9% | -37.3% | |
| Pretax Profit Margin | 13.2% | 5.8% | -21.2% | -12.3% | -37.2% | |
| Continuous Operations Profit Margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | |
| Net Profit Margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | |
| Bottom Line Profit Margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% | |
| Current Ratio | 8.148 | 4.734 | 4.664 | 3.971 | 3.790 | |
| Quick Ratio | 7.805 | 4.458 | 4.401 | 3.743 | 3.615 | |
| Solvency Ratio | 0.910 | 0.384 | -0.667 | -0.090 | -0.595 | |
| Cash Ratio | 6.049 | 3.041 | 3.534 | 2.463 | 2.700 | |
| Price To Earnings Ratio | 50.119 | 123.750 | -26.971 | -46.529 | -37.117 | |
| Price To Earnings Growth Ratio | 0.308 | -0.942 | -0.270 | 0.861 | -0.544 | |
| Forward Price To Earnings Growth Ratio | 0.308 | -0.942 | -0.270 | 0.861 | -0.544 | |
| Price To Earnings Diluted Ratio | 51.341 | 127.742 | -26.971 | -46.529 | -37.117 | |
| Price To Earnings Diluted Growth Ratio | 0.312 | -0.980 | -0.270 | 0.861 | -0.544 | |
| Price To Book Ratio | 2.526 | 2.576 | 1.914 | 1.579 | 2.551 | |
| Price To Sales Ratio | 6.397 | 6.795 | 5.535 | 5.726 | 12.742 | |
| Price To Free Cash Flow Ratio | 26.126 | 47.467 | 58.330 | -1,674.421 | -75.603 | |
| Price To Operating Cash Flow Ratio | 24.272 | 40.332 | 45.191 | 225.330 | -88.456 | |
| Debt To Assets Ratio | 0.028 | 0.039 | 0.011 | 0.013 | 0.016 | |
| Debt To Equity Ratio | 0.030 | 0.043 | 0.012 | 0.014 | 0.017 | |
| Debt To Capital Ratio | 0.029 | 0.041 | 0.012 | 0.014 | 0.017 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.074 | 1.106 | 1.068 | 1.076 | 1.083 | |
| Working Capital Turnover Ratio | 1.432 | 1.721 | 1.759 | 1.625 | 0.816 | |
| Operating Cash Flow Ratio | 2.274 | 0.955 | 0.722 | 0.120 | -0.493 | |
| Operating Cash Flow Sales Ratio | 0.264 | 0.168 | 0.122 | 0.025 | -0.144 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.929 | 0.850 | 0.775 | -0.135 | 1.170 | |
| Debt Service Coverage Ratio | 0.000 | 23,799.500 | -3,146.733 | -35.929 | -39.545 | |
| Interest Coverage Ratio | 0.000 | 8,071.000 | -5,719.667 | -207.480 | -339.846 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -28.058 | |
| Operating Cash Flow Coverage Ratio | 3.437 | 1.480 | 3.501 | 0.512 | -1.677 | |
| Capital Expenditure Coverage Ratio | 14.086 | 6.653 | 4.440 | 0.881 | -5.882 | |
| Dividend Paid And Capex Coverage Ratio | 14.086 | 6.653 | 4.440 | 0.881 | -5.882 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 33.314 | 57.727 | -36.322 | -223.225 | -43.912 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.6% | ▲2.7% | ▲2.2% |
| Ebit Margin | 13.2% | ▲7.4% | ▲23.5% |
| Ebitda Margin | 17.3% | ▲6.3% | ▲20.3% |
| Operating Profit Margin | 14.3% | ▲10.7% | ▲25.7% |
| Pretax Profit Margin | 13.2% | ▲7.4% | ▲23.5% |
| Continuous Operations Profit Margin | 12.8% | ▲7.4% | ▲22.7% |
| Net Profit Margin | 12.8% | ▲7.4% | ▲22.7% |
| Bottom Line Profit Margin | 12.8% | ▲7.4% | ▲22.7% |
| Current Ratio | 8.148 | ▲3.414 | ▲3.087 |
| Quick Ratio | 7.805 | ▲3.348 | ▲3.001 |
| Solvency Ratio | 0.910 | ▲0.526 | ▲0.922 |
| Cash Ratio | 6.049 | ▲3.009 | ▲2.492 |
| Price To Earnings Ratio | 50.119 | ▼-73.631 | ▲37.469 |
| Price To Earnings Growth Ratio | 0.308 | ▲1.250 | ▲0.426 |
| Forward Price To Earnings Growth Ratio | 0.308 | ▲1.250 | ▲0.426 |
| Price To Earnings Diluted Ratio | 51.342 | ▼-76.400 | ▲37.648 |
| Price To Earnings Diluted Growth Ratio | 0.312 | ▲1.292 | ▲0.436 |
| Price To Book Ratio | 2.526 | ▼-0.049 | ▲0.297 |
| Price To Sales Ratio | 6.397 | ▼-0.397 | ▼-1.042 |
| Price To Free Cash Flow Ratio | 26.127 | ▼-21.340 | ▲349.747 |
| Price To Operating Cash Flow Ratio | 24.272 | ▼-16.061 | ▼-25.062 |
| Debt To Assets Ratio | 0.028 | ▼-0.011 | ▲0.007 |
| Debt To Equity Ratio | 0.030 | ▼-0.013 | ▲0.007 |
| Debt To Capital Ratio | 0.029 | ▼-0.012 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.074 | ▼-0.032 | ▼-0.007 |
| Working Capital Turnover Ratio | 1.432 | ▼-0.289 | ▼-0.038 |
| Operating Cash Flow Ratio | 2.274 | ▲1.319 | ▲1.558 |
| Operating Cash Flow Sales Ratio | 0.264 | ▲0.095 | ▲0.176 |
| Free Cash Flow Operating Cash Flow Ratio | 0.929 | ▲0.079 | ▲0.211 |
| Debt Service Coverage Ratio | 0.000 | ▼-23799.500 | ▼-4115.459 |
| Interest Coverage Ratio | 0.000 | ▼-8071.000 | ▼-360.801 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲5.612 |
| Operating Cash Flow Coverage Ratio | 3.437 | ▲1.957 | ▲1.987 |
| Capital Expenditure Coverage Ratio | 14.086 | ▲7.432 | ▲10.050 |
| Dividend Paid And Capex Coverage Ratio | 14.086 | ▲7.432 | ▲10.050 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 33.314 | ▼-24.413 | ▲75.798 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.31B | $3.03B | $2.00B | $1.70B | $2.80B | |
| Enterprise value | $2.99B | $2.84B | $1.79B | $1.56B | $2.64B | |
| EV / Sales | 5.77x | 6.37x | 4.97x | 5.25x | 12.04x | |
| EV / Op. cash flow | 21.90x | 37.82x | 40.58x | 206.81x | -83.58x | |
| EV / Free cash flow | 23.58x | 44.52x | 52.38x | -1536.82x | -71.43x | |
| EV / EBITDA | 33.31x | 57.73x | -36.32x | -223.22x | -43.91x | |
| Net debt / EBITDA | -3.60x | -3.83x | 4.12x | 19.99x | 2.56x | |
| Current ratio | 8.15x | 4.73x | 4.66x | 3.97x | 3.79x | |
| Income quality | 2.05x | 3.11x | -0.59x | -0.21x | 0.42x | |
| Graham number | $18 | $10 | — | — | — | |
| Graham net-net | $5 | $3 | $3 | $2 | $2 | |
| Tax burden | 97.3% | 93.8% | 97.1% | 100.4% | 92.5% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.5% | 100.3% | |
| Working capital | $428.4M | $293.6M | $224.4M | $186.0M | $179.0M | |
| Invested capital | $1.34B | $1.21B | $1.05B | $1.09B | $1.12B | |
| Return on assets | 4.7% | 1.9% | -6.7% | -3.2% | -6.4% | |
| Operating ROA | 5.5% | 1.3% | -7.6% | -3.5% | -10.0% | |
| Return on tangible assets | 12.1% | 5.3% | -23.0% | -12.8% | -27.3% | |
| Return on equity | 5.1% | 2.1% | -7.1% | -3.4% | -6.9% | |
| Return on invested capital | 5.3% | 1.2% | -7.9% | -3.7% | -6.7% | |
| Return on capital employed | 5.5% | 1.3% | -8.1% | -3.8% | -7.3% | |
| Earnings yield | 2.0% | 0.8% | -3.7% | -2.2% | -2.7% | |
| Free cash flow yield | 3.8% | 2.1% | 1.7% | -0.1% | -1.3% | |
| Capex / Op. cash flow | 7.1% | 15.0% | 22.5% | 113.5% | -17.0% | |
| Capex / Depreciation | 45.2% | 48.1% | 36.6% | 33.0% | 27.4% | |
| Capex / Sales | 1.9% | 2.5% | 2.8% | 2.9% | 2.4% | |
| SG&A / Sales | 40.8% | 46.2% | 51.0% | 58.7% | 82.5% | |
| R&D / Sales | 13.7% | 15.5% | 15.9% | 13.7% | 13.6% | |
| Stock comp / Sales | 8.4% | 8.1% | 9.2% | 9.0% | 10.3% | |
| Intangibles / Total assets | 60.9% | 65.2% | 71.0% | 75.3% | 76.7% | |
| Days sales outstanding | 32d | 38d | 41d | 54d | 69d | |
| Days payables outstanding | 11d | 21d | 42d | 43d | 61d | |
| Operating cycle | 79d | 92d | 93d | 106d | 124d | |
| Cash conversion cycle | 69d | 71d | 51d | 63d | 63d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+9.2%EV / Sales ▼-9.4%EV / EBITDA ▼-42.3%EV / Op. cash flow ▼-15.922Earnings yield ▲+0.012Graham number ▲+7.344
Profitability
Return on equity ▲+0.030Return on assets ▲+0.029Return on invested capital ▲+0.041Return on capital employed ▲+0.042Operating ROA ▲+0.041Income quality ▼-1.057Tax burden ▲+0.035
Efficiency
Days sales outstanding ▼-6.575Days payables outstanding ▼-10.677Operating cycle ▼-12.617Cash conversion cycle ▼-1.940Capex / Sales ▼-0.007R&D / Sales ▼-0.019
Balance-sheet strength
Current ratio ▲+3.414Net debt / EBITDA ▲+0.224Working capital ▲+134805000.000Invested capital ▲+130655000.000Intangibles / Total assets ▼-0.043
Change over 5 years
Valuation
Market cap ▲+18.3%EV / Sales ▼-52.0%EV / EBITDA ▲+175.9%EV / Op. cash flow ▲+105.478Earnings yield ▲+0.047
Profitability
Return on equity ▲+0.120Return on assets ▲+0.111Return on invested capital ▲+0.121Return on capital employed ▲+0.128Operating ROA ▲+0.154Income quality ▲+1.636Tax burden ▲+0.047
Efficiency
Days sales outstanding ▼-37.419Days payables outstanding ▼-49.966Operating cycle ▼-44.752Cash conversion cycle ▲+5.214Capex / Sales ▼-0.006R&D / Sales ▲+0.001
Balance-sheet strength
Current ratio ▲+4.359Net debt / EBITDA ▼-6.168Working capital ▲+249488000.000Invested capital ▲+222805000.000Intangibles / Total assets ▼-0.158
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-02-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-12 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-16 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2023-10-16 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-09-15 | Josh S. Gottheimer | Sale | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2020-12-23 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-10 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-08 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-10-29 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-01-17 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-12-24 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-12-12 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-12-06 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-01 Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
- 2026-09-01 Canada Pension Plan Investment Board Purchases Shares of 20,700 Veracyte, Inc. $VCYT Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 20,700 shares of the biotechnology company''s stock, valued at approximately $1,216,000. Several other hedge funds and
- 2026-08-30 Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYT Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,948 shares of the biotechnology company''s stock, valued at approximately $1,583,000. Other hedge funds and other institutional investors have also recently
- 2026-08-27 Bamco Inc. NY Invests $38.22 Million in Veracyte, Inc. $VCYT Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 650,686 shares of the biotechnology company''s stock, valued at approximately $38,215,000. Bamco Inc. NY owned approximately 0.81% of Veracyte at the
- 2026-08-26 Is it Worth Adding Veracyte Stock to Your Portfolio Now? VCYT''s Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
- 2026-08-25 VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity? Veracyte''s 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
- 2026-08-17 Down 30.2% in 4 Weeks, Here''s Why Veracyte (VCYT) Looks Ripe for a Turnaround Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 2026-08-13 Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT Bank of America Corp DE grew its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 14.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,448,897 shares of the biotechnology company''s stock after buying an additional 185,929 shares during the period.
- 2026-08-10 Veracyte: Diagnostics With Favorable Economics Veracyte''s core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT''s potential as a long-term cash flow machine. Moreover, VCYT''s Prosigna and TrueMRD add more long-term upside, which management hasn''t yet included in its recent 2026 testing-revenue guidance.
- 2026-08-09 Veracyte: Core Growth Funds Prosigna And TrueMRD Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.